CannaPharmaRx Inc
OTC:CPMD

Watchlist Manager
CannaPharmaRx Inc Logo
CannaPharmaRx Inc
OTC:CPMD
Watchlist
Price: 0.004 USD 14.29% Market Closed
Market Cap: 2.7m USD

Relative Value

CPMD doesn't have a meaningful market cap.

The Relative Value of one CPMD stock under the Base Case scenario is 0.004 USD. Compared to the current market price of 0.004 USD, CannaPharmaRx Inc is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CPMD Relative Value
Base Case
0.004 USD
Undervaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
18
Median 3Y
1.5
Median 5Y
0
Industry
2.6
vs History
vs Industry
45
Median 3Y
-0.3
Median 5Y
-0.3
Industry
21.6
vs History
vs Industry
49
Median 3Y
-1.8
Median 5Y
-1.8
Industry
16.5
vs History
20
vs Industry
22
Median 3Y
11.8
Median 5Y
-1.8
Industry
22.5
vs History
vs Industry
Median 3Y
-0.2
Median 5Y
-0.2
Industry
2.3
vs History
23
vs Industry
6
Median 3Y
10.1
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
-34.7
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-5.5
Industry
13
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-5.6
Industry
16.6
vs History
vs Industry
41
Median 3Y
-8.1
Median 5Y
-8.4
Industry
15.8
vs History
vs Industry
31
Median 3Y
-8.1
Median 5Y
-8.3
Industry
19.1
vs History
57
vs Industry
18
Median 3Y
2.4
Median 5Y
2.8
Industry
1.9

Multiples Across Competitors

CPMD Competitors Multiples
CannaPharmaRx Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
CannaPharmaRx Inc
OTC:CPMD
2.6m USD 1.9 -0.5 -5.6 -5.8
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 16.4 52.8 35.5 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 5.5 20.3 16.6 21.5
CH
Roche Holding AG
SIX:ROG
254.3B CHF 4.1 27 11.5 13.5
UK
AstraZeneca PLC
LSE:AZN
208.7B GBP 4.8 29.7 108.2 158.4
CH
Novartis AG
SIX:NOVN
202.5B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
249.5B USD 3.9 13 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.6 9.5 11
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
CA
CannaPharmaRx Inc
OTC:CPMD
Average P/E: 23.6
Negative Multiple: -0.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
27
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
CannaPharmaRx Inc
OTC:CPMD
Average EV/EBITDA: 438.7
Negative Multiple: -5.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
CannaPharmaRx Inc
OTC:CPMD
Average EV/EBIT: 1 881.1
Negative Multiple: -5.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3